Global Psoriatic Arthritis Therapeutics Market Report and Forecast 2023-2031

Global Psoriatic Arthritis Therapeutics Market Report and Forecast 2023-2031


Global Psoriatic Arthritis Therapeutics Market Outlook


The growth of the global psoriatic arthritis therapeutics market size is being driven by the increasing prevalence of psoriatic arthritis and increasing awareness about the disease across the globe. The market value is anticipated to grow at a CAGR of 6.5% during the forecast period of 2023-2031.

Psoriatic Arthritis Therapeutics: Introduction

Psoriatic arthritis is a type of inflammatory arthritis that affects some individuals with psoriasis, a skin condition that causes red, scaly patches on the skin. Psoriatic arthritis can cause joint pain, stiffness, and swelling, as well as damage to joints and other parts of the body. It can also cause nail changes and eye problems. Psoriatic arthritis affects both men and women and can occur at any age, but typically develops in people between the ages of 30 and 50. The exact cause of psoriatic arthritis is unknown, but it is believed to be an autoimmune disorder. There is no cure for psoriatic arthritis, but treatment can help manage symptoms and prevent joint damage.

Psoriatic Arthritis: Epidemiology

Psoriatic arthritis is a chronic inflammatory disease that affects the joints and the skin. The exact prevalence of psoriatic arthritis is unknown, but it is estimated to affect approximately 0.3% to 1% of the general population worldwide. It affects both men and women equally, and typically develops between the ages of 30 and 50. It is more common in people with psoriasis, a skin condition that causes red, scaly patches to appear on the skin.

Global Psoriatic Arthritis Therapeutics Market Segmentations


Market Breakup by Drug Class
  • Nonsteroidal anti-inflammatory drugs (NSAIDs)
  • Disease-modifying antirheumatic drugs (DMARDs)
  • Immunosuppressants
  • Biological Agents
  • Others
Market Breakup by Product Type
  • Prescription
  • Over The Counter
Market Breakup by Route of Administration
  • Oral
  • Parenteral
  • Topical
Market Breakup by Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
Market Breakup by Region

North America
  • United States of America
  • Canada
Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Others
Asia Pacific
  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others
Latin America
  • Brazil
  • Argentina
  • Mexico
  • Others
Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Global Psoriatic Arthritis Therapeutics Market Scenario


Psoriatic arthritis is a chronic inflammatory arthritis that affects people with psoriasis. The global psoriatic arthritis therapeutics market is expected to experience significant growth in the forecast period from 2023 to 2031. The increasing prevalence of psoriatic arthritis, rising awareness about the disease, and the introduction of novel therapeutics are the major factors driving the market growth.

By route of administration, the market is segmented into oral, parenteral, and others. The parenteral segment is expected to witness significant growth in the forecast period due to the increasing use of biologics, which are mainly administered through the parenteral route.

Geographically, North America held the largest share of the psoriatic arthritis therapeutics market in 2020, followed by Europe and Asia Pacific. The increasing prevalence of psoriatic arthritis in North America, coupled with the availability of advanced healthcare infrastructure and favourable reimbursement policies, are the major factors contributing to the dominance of this region.

In the forecast period, Asia Pacific is expected to witness significant growth due to the increasing prevalence of psoriatic arthritis in the region, rising healthcare expenditure, and growing awareness about the disease.

Key Players in the Global Psoriatic Arthritis Therapeutics Market

The report gives an in-depth analysis of the key players involved in the global psoriatic arthritis therapeutics market. The companies included in the market are as follows:
  • AbbVie Inc.
  • Janssen Global Services, LLC (Johnson & Johnson)
  • Novartis AG
  • Amgen Inc.
  • Biogen Inc.
  • Pfizer Inc.
  • Eli Lilly and Company
  • UCB S.A.
  • Bristol-Myers Squibb Company
  • Merck & Co. Inc.


1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Psoriatic Arthritis Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Psoriatic Arthritis Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Psoriatic Arthritis Epidemiology (2016-2031)
5.3 Europe Psoriatic Arthritis Epidemiology (2016-2031)
5.4 Asia-Pacific Psoriatic Arthritis Epidemiology (2016-2031)
5.5 Latin America Psoriatic Arthritis Epidemiology (2016-2031)
5.6 Middle East & Africa Psoriatic Arthritis Epidemiology (2016-2031)
6 Global Psoriatic Arthritis Therapeutics Market Overview
6.1 Global Psoriatic Arthritis Therapeutics Market Historical Value (2016-2022)
6.2 Global Psoriatic Arthritis Therapeutics Market Forecast Value (2023-2031)
7 Global Psoriatic Arthritis Therapeutics Market Landscape
7.1 Psoriatic Arthritis Therapeutics: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Psoriatic Arthritis Therapeutics: Product Landscape
7.2.1 Analysis by Drug Class
7.2.2 Analysis by Product Type
7.2.3 Analysis by Route of Administration
7.2.4 Analysis by Distribution Channel
8 Psoriatic Arthritis Therapeutics Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Psoriatic Arthritis Therapeutics Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Psoriatic Arthritis Therapeutics Market Segmentation
11.1 Global Psoriatic Arthritis Therapeutics Market by Drug Class
11.1.1 Market Overview
11.1.2 Nonsteroidal anti-inflammatory drugs (NSAIDs)
11.1.3 Disease-modifying antirheumatic drugs (DMARDs)
11.1.4 Immunosuppressants
11.1.5 Biological Agents
11.1.6 Others
11.2 Global Psoriatic Arthritis Therapeutics Market by Product Type
11.2.1 Market Overview
11.2.2 Prescription
11.2.3 Over The Counter
11.3 Global Psoriatic Arthritis Therapeutics Market by Route of Administration
11.3.1 Market Overview
11.3.2 Oral
11.3.3 Parenteral
11.3.4 Topical
11.4 Global Psoriatic Arthritis Therapeutics Market by Distribution Channel
11.4.1 Market Overview
11.4.2 Hospital Pharmacies
11.4.3 Retail Pharmacies
11.4.4 Online Pharmacies
11.5 Global Psoriatic Arthritis Therapeutics Market by Region
11.5.1 Market Overview
11.5.2 North America
11.5.3 Europe
11.5.4 Asia Pacific
11.5.5 Latin America
11.5.6 Middle East and Africa
12 North America Psoriatic Arthritis Therapeutics Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Psoriatic Arthritis Therapeutics Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Psoriatic Arthritis Therapeutics Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Psoriatic Arthritis Therapeutics Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Psoriatic Arthritis Therapeutics Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
17.1.5 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Partnership and Collaborations Analysis
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 AbbVie Inc.
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 Janssen Global Services, LLC (Johnson & Johnson)
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Novartis AG
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 Amgen Inc.
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 Biogen Inc.
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 Pfizer Inc.
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 Eli Lilly and Company
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 UCB S.A.
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 Bristol-Myers Squibb Company
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 Merck & Co. Inc.
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
24 Psoriatic Arthritis Therapeutics - Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings